Close

Registration is free and only takes a moment. If you have already registered, please log in now.

Create Account
Forgot your password?
Log In
  • Links
  • Publisher Full Text
  • Authors
  • Emery P
  • Buch MH
  • MESH
  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Biological Therapy
  • Female
  • Humans
  • Male
  • Methotrexate
  • Tumor Necrosis Factor-alpha

Unbound MEDLINE

Towards an optimum strategy in rheumatoid arthritis.

Links

  • Publisher Full Text
  • Authors

    Emery P, Buch MH

    Institution

    Division of Rheumatic and Musculoskeletal Disease, Leeds Institute of Molecular Medicine, University of Leeds, Chapel Allerton Hospital, Leeds LS7 4SA, UK. p.emery@leeds.ac.uk

    Source

    Lancet 379:9827 2012 May 5 pg 1682-4

    MeSH

    Antibodies, Monoclonal
    Antirheumatic Agents
    Arthritis, Rheumatoid
    Biological Therapy
    Female
    Humans
    Male
    Methotrexate
    Tumor Necrosis Factor-alpha

    Pub Type(s)

    Comment
    Journal Article

    Language

    eng

    PubMed ID

    22464342

    Related Citations

    • Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab.
    • Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?
    • Adalimumab for rheumatoid arthritis?
    • New drugs for rheumatoid arthritis.
    • Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study.
    • Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade.
    • Treatment of rheumatoid arthritis: we are getting there.
    • Rheumatoid arthritis.
    More
    unbound logo
    • Home »
    • Contact Us »
    • Help »
    • Privacy / Disclaimer »
    • Terms of Service »
    • Log In »
    • twitter
    • facebook
    © 2000–2013 Unbound Medicine, Inc. All rights reserved